Lakewood-Amedex advances Nu-3 in groundbreaking trial for resistant diabetic foot ulcers

Lakewood-Amedex has secured approvals to launch a Phase 2a study of Nu-3, its antimicrobial gel, targeting challenging resistant bacteria in diabetic foot ulcers, with clinical expertise brought in to bolster development. Lakewood-Amedex Biotherapeutics said it has secured the institutional approvals…















